Literature DB >> 19609296

Heat-induced transcription of diphtheria toxin A or its variants, CRM176 and CRM197: implications for pancreatic cancer gene therapy.

P Fogar1, F Navaglia, D Basso, C-F Zambon, L Moserle, S Indraccolo, A Stranges, E Greco, E Fadi, A Padoan, G Pantano, M C Sanzari, S Pedrazzoli, C Montecucco, M Plebani.   

Abstract

Vectors combining the heat shock proteins (HSPs) promoter with the catalytic subunit A of the diphtheria toxin (DTA) or its variants, cross-reacting material (CRM) 176 and 197, were engineered to investigate the effect of bacterial toxins on pancreatic cancer (PC) cells. Three heat-inducible enhanced green fluorescent protein (eGFP)-expression vectors were obtained: V1 (91% homology to HSPA6), V2 (five heat shock elements upstream the minimal HSPA6 promoter) and V3 (V1 and V2 combined). The highest eGFP transcription and translation levels were found in V3 transfected PC cells. The V3 promoter was used to control DTA, CRM176 and CRM197 expression, treatment response being investigated in four PC cell lines. DTAwt or CRM176 transfected cell growth was completely arrested after heat shock. CRM197 toxin presumed to be inactive, caused mild distress at 37 degrees C and induced a 25-50% reduction in cell growth after heat shock. Preliminary in vivo findings showed that heat treatment arrests tumor growth in DTA197 stably transfected PSN1 cells. In conclusion, the efficient HSP promoter identified in this study may be extremely useful in controlling the transcription of toxins such as CRM197, which have lethal dose-related effects, and may thus be a promising tool in PC gene therapy in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19609296     DOI: 10.1038/cgt.2009.48

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  7 in total

1.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

2.  The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells.

Authors:  Lvxia Dai; Xiaoping Yu; Sizhou Huang; Yanjuan Peng; Jianmin Liu; Tian Chen; Xin Wang; Qiaofeng Liu; Yanfeng Zhu; Dengbang Chen; Xiaohua Li; Yu Ou; Yi Zou; Qu Pan; Kang Cao
Journal:  Cancer Biol Ther       Date:  2020-12-30       Impact factor: 4.742

Review 3.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

4.  Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential.

Authors:  Rekha Khandia; Bramhadev Pattnaik; Katherukamem Rajukumar; Atul Pateriya; Sandeep Bhatia; Harshad Murugkar; Anil Prakash; Hare Krishna Pradhan; Kuldeep Dhama; Ashok Munjal; Sunil K Joshi
Journal:  Oncotarget       Date:  2017-05-30

Review 5.  Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Authors:  Fatemeh Shafiee; Marc G Aucoin; Ali Jahanian-Najafabadi
Journal:  Front Microbiol       Date:  2019-10-18       Impact factor: 5.640

6.  Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A.

Authors:  Baoshun Lin; Anding Gao; Rui Zhang; Hongyu Ma; Haifeng Shen; Qiong Hu; Hua Zhang; Meng Zhao; Xiaopeng Lan; Kuancan Liu
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

Review 7.  Synthetic immunity by remote control.

Authors:  Lena Gamboa; Ali H Zamat; Gabriel A Kwong
Journal:  Theranostics       Date:  2020-02-19       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.